Conference Coverage

ECTRIMS/EAN statement on COVID-19 vaccination in patients with MS


 

FROM ECTRIMS 2021

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have produced a joint position statement on COVID-19 vaccination for patients with multiple sclerosis (MS).

The statement was released at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The statement concludes that the COVID-19 vaccines that are currently available are safe for patients with MS. Further, it states that the vaccines confer the same protection for patients with MS as they do for the general population. Exceptions may be patients taking the S1P modulator fingolimod and anti-CD20 drugs. For these patients, antibody responses have been shown to be reduced.

This position statement will be published on the ECTRIMS and EAN websites. Owing to the shifting, ongoing nature of evidence, the position statement will be updated periodically.

Presenting the statement, Mauricio Farez, MD, Fundacion FLENI, Buenos Aires, concluded: “Overall, MS patients do not seem to develop more severe forms of COVID-19 as compared with healthy controls, but patients with greater disability, anti-CD20 treatment, or those with recent steroid use have a higher risk of severe disease.”

“So far there are no specific contraindications for any COVID vaccines in MS patients reported,” he added. “We should work with our patients to keep them safe with vaccines while optimizing treatment strategies and MS management, in particular for those treated with anti-CD20 and S1P modulators.”

Risk for COVID-19 among patients with MS

On the issue of whether patients with MS are at higher risk for COVID-19 or for having a more severe form of the disease, Dr. Farez noted that studies published to date are reassuring and don’t suggest major problems regarding safety.

The main factors that are associated with more serious forms of COVID in patients with MS are similar to those in the general population. These include age, obesity, diabetes, male sex, and Black race.

As for any risk associated with MS therapies, interferons and glatiramer acetate do not increase the risk of getting COVID-19 or worsen the clinical course of the disease. Fingolimod, teriflunomide, natalizumab, and dimethyl fumarate also do not seem to negatively affect risk for COVID-19, according to the statement.

However, several studies have shown that anti-CD20 therapies, such as ocrelizumab, and steroid pulses can confer an increased risk for COVID-19.

COVID-19 vaccine safety

Four COVID-19 vaccines are licensed for use in the European Union. These include two mRNA vaccines – Spikevax (Moderna) and Comimaty (Pfizer) – and two adenovirus-based vaccines, one from Janssen (J&J) and the other from AstraZeneca. Five other COVID-19 vaccines are under review and may be available in the future.

All the currently available vaccines can be administered to patients with MS, including patients receiving immunosuppressant disease-modifying therapies, the statement notes.

In real-life clinical practice, no red flags have been observed for patients with MS who have received mRNA vaccines to date. Nevertheless, because immunocompromised patients and those taking immunomodulators were excluded from trials, continued surveillance for immune-mediated adverse effects is warranted, Dr. Farez said.

Regarding possible effects of vaccines on MS relapses/disability, no significant adverse effects occurred in a study conducted in Israel (by Achiron and colleagues) that involved 435 patients with MS who were fully vaccinated with the Pfizer mRNA vaccine. The relapse rate was 1.6%, similar to the rate among patients who did not have MS. A study by Di Filippo and colleagues showed no significant changes in relapse rate in the 2 months following immunization with the Pfizer vaccine among 324 patients with MS.

“There are no specific contraindications to any of the vaccines particularly for MS patients compared with the general population,” Dr. Farez noted.

Pages

Recommended Reading

Opioid use common for pain in multiple sclerosis
Journal of Clinical Outcomes Management
NfL levels linked to worse disability in real-world MS
Journal of Clinical Outcomes Management
Certain DMTs in MS may attenuate COVID-19 vaccines
Journal of Clinical Outcomes Management
Neurologic drug prices jump 50% in five years
Journal of Clinical Outcomes Management
Common MS treatment wears off more quickly in Black patients
Journal of Clinical Outcomes Management
Some MS treatments may heighten COVID risk
Journal of Clinical Outcomes Management
Investigational drug reduces brain lesions in highly active MS
Journal of Clinical Outcomes Management
A less expensive, more convenient treatment option for MS?
Journal of Clinical Outcomes Management
Guidance on additional COVID-19 vaccine dose for MS patients
Journal of Clinical Outcomes Management
NIH to study COVID vaccine booster in people with autoimmune disease
Journal of Clinical Outcomes Management